Risk of Heart Failure Hospitalization Associated With Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis-Stimulating Agents: A Nationwide Claims-Based Cohort Study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Heart Failure Hospitalization Risk with Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Compared to Erythropoiesis-Stimulating Agents: A Nationwide Claims Analysis

  • By

  • Yuki Kunitsu

  • Keiko Ikuta

  • Daiki Hira

  • Shunsaku Nakagawa

  • Tomohiro Terada

  • August 29, 2026

Share

Original Source(s)

Risk of Heart Failure Hospitalization Associated With Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis-Stimulating Agents: A Nationwide Claims-Based Cohort Study

  • by Yuki Kunitsu, Keiko Ikuta, Daiki Hira, Shunsaku Nakagawa, Tomohiro Terada

  • August 29, 2026

Related Content

Efficacy and safety of quadruple therapy versus triple therapy in patients with heart failure with preserved ejection fraction: a propensity score-matched real-world study

Validation of femoral pressure-derived assessment of effective arterial elastance in porcine ischemic cardiogenic shock

Myocardial function recovery in peripartum cardiomyopathy: the role of global longitudinal strain and myocardial work